Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 SPM-927 (Schwarz Pharma).

Literature DB >> 12789603

SPM-927 (Schwarz Pharma).

Abstract

Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain.

Entities: Disease

Mesh：

Substances：

Year: 2003 PMID： 12789603

Source DB: PubMed Journal: IDrugs ISSN： 1369-7056

Keyword Cloud
Cited

14 in total

1. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration.

Authors: Willi Cawello; Hilmar Boekens; Rainer Bonn
Journal: Eur J Drug Metab Pharmacokinet Date: 2012-04-29 Impact factor: 2.441

Review 2. Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors: Michael A Rogawski
Journal: Epilepsy Res Date: 2006-04-18 Impact factor: 3.045

Review 3. Lacosamide.

Authors: Pamela Doty; G David Rudd; Thomas Stoehr; Dirk Thomas
Journal: Neurotherapeutics Date: 2007-01 Impact factor: 7.620

4. New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

Authors: Steve S Chung
Journal: Ther Adv Neurol Disord Date: 2010-03 Impact factor: 6.570

Review 5. Pharmacotherapy of epilepsy: newly approved and developmental agents.

Authors: Linda J Stephen; Martin J Brodie
Journal: CNS Drugs Date: 2011-02 Impact factor: 5.749

Review 6. Lacosamide and epilepsy.

Authors: Jacklyn A Harris; Julie A Murphy
Journal: CNS Neurosci Ther Date: 2010-10-15 Impact factor: 5.243

SPM-927 (Schwarz Pharma).

1. Absorption, disposition, metabolic fate and elimination of the anti-epileptic drug lacosamide in humans: mass balance following intravenous and oral administration.

Review 2. Diverse mechanisms of antiepileptic drugs in the development pipeline.

Review 3. Lacosamide.

4. New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

Review 5. Pharmacotherapy of epilepsy: newly approved and developmental agents.

Review 6. Lacosamide and epilepsy.

7. Lacosamide modulates interictal spiking and high-frequency oscillations in a model of mesial temporal lobe epilepsy.

8. Clinical perspectives on lacosamide.

9. Efficacy and safety of lacosamide in painful diabetic neuropathy.

10. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.